98%
921
2 minutes
20
Purpose: To evaluate the outcomes of gonadotropin therapy (GT) using human chorionic gonadotropin (hCG) and recombinant follicle-stimulating hormone (rFSH) for inducing spermatogenesis in men with prepubertal-onset hypogonadotropic hypogonadism (HH), compare these outcomes between men with congenital and acquired etiologies, and identify factors associated with successful spermatogenesis.
Materials And Methods: This retrospective study included 65 men with prepubertal-onset HH who underwent GT to induce spermatogenesis. Baseline assessments included serum luteinizing hormone (LH), FSH, and testosterone levels, and testicular volume (TV) measurements. Treatment began with hCG injections administered thrice weekly for four weeks, followed by combined rFSH and hCG therapy. Serum testosterone levels were measured after hCG pretreatment. TV and semen analyses were evaluated every three months following the rFSH addition. Successful spermatogenesis was defined as the detection of at least one sperm in a semen sample.
Results: Median baseline testosterone, LH, and FSH levels were 0.10 ng/mL, 0.05 IU/L, and 0.50 IU/L, respectively, with a median baseline TV of 4.0 mL. After hCG pretreatment, median serum testosterone level increased to 3.16 ng/mL. Treatment outcomes were analyzed in 50 patients who continued GT until spermatogenesis induction or for at least 12-months. Following therapy, median TV increased to 9.0 mL. Spermatogenesis was successfully induced in 41 patients (82.0%), with a median induction time of 7.5-months. In these patients, median sperm concentration, total motility, and morphology were 5.2×10⁶/mL, 35%, and 4%, respectively. Success of spermatogenesis induction did not differ between patients with congenital and acquired HH etiologies. Larger baseline TV was the only predictor of successful outcomes. Earlier spermatogenesis was correlated with larger baseline TV. Among six patients seeking conception, four achieved conception.
Conclusions: GT can successfully induce spermatogenesis in 82% of patients with prepubertal-onset HH, regardless of etiology. Baseline TV was confirmed as a predictor of successful outcomes and earlier spermatogenesis induction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5534/wjmh.250117 | DOI Listing |
World J Mens Health
August 2025
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Purpose: To evaluate the outcomes of gonadotropin therapy (GT) using human chorionic gonadotropin (hCG) and recombinant follicle-stimulating hormone (rFSH) for inducing spermatogenesis in men with prepubertal-onset hypogonadotropic hypogonadism (HH), compare these outcomes between men with congenital and acquired etiologies, and identify factors associated with successful spermatogenesis.
Materials And Methods: This retrospective study included 65 men with prepubertal-onset HH who underwent GT to induce spermatogenesis. Baseline assessments included serum luteinizing hormone (LH), FSH, and testosterone levels, and testicular volume (TV) measurements.
Pediatr Dermatol
February 2024
Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, Bochum, Germany.
Eur J Gastroenterol Hepatol
November 2014
aDepartment of Pediatrics, Division of Gastroenterology, Cantons Hospital of Fribourg, Fribourg bUniversity Hospital of Lausanne, Institute of Social and Preventive Medicine cDivision of Gastroenterology, University Children's Hospital of Lausanne, Lausanne dDivision of Gastroenterology and Nutritio
Objectives: Growth retardation is a frequent complication of paediatric inflammatory bowel disease (IBD). Only a few studies report the final height of these patients, with controversial results. We compared adult height of patients with paediatric IBD with that of patients with adult-onset disease.
View Article and Find Full Text PDFEndocr Metab Immune Disord Drug Targets
September 2012
Endocrinology and Metabolic Diseases, University of Bari, Bari, Italy.
Prepuberal-onset (PRHH) and postpuberal-onset (PSHH) Hypogonadotropic Hypogondism (HH) refer to a heterogeneous group of patients, showing a broad spectrum of clinical signs and symptoms of androgen deficiency in consideration of the different possible aetiologies and the age at onset. These patients, though, required Gonadotropin treatment (GnTh) by means of administration of both the β Human Chorionic Gonodadotropin (β HCG) and the Follicle Stimulating Hormone (FSH) to obtain mature sperms in the ejaculate aiming to reach fertility levels. However, the response to GnTh is always unpredictable concerning either the effectiveness or the duration of the therapy.
View Article and Find Full Text PDFFront Horm Res
February 2009
Centre for Andrology and Sexual Medicine, Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Hypogonadism in males is a clinical syndrome complex which comprises symptoms with or without signs as well as biochemical evidence of testosterone deficiency. The diagnosis of hypogonadism thus includes both clinical history and examination as well as biochemical assessment of serum testosterone levels. Hypogonadal symptoms depend on the age at onset of hypogonadism, severity of the deficiency, its duration and sensitivity to androgen action.
View Article and Find Full Text PDF